Patents by Inventor Christoph SCHRAEDER

Christoph SCHRAEDER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240150429
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 19, 2024
    Publication date: May 9, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Lena WULLKOPF, Christoph SCHRAEDER, Jens FRITSCHE, Daniel Johannes KOWALEWSKI, Michael ROEMER, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240150430
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 19, 2024
    Publication date: May 9, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Lena WULLKOPF, Christoph SCHRAEDER, Jens FRITSCHE, Daniel Johannes KOWALEWSKI, Michael ROEMER, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240141013
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 18, 2023
    Publication date: May 2, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Lena WULLKOPF, Christoph SCHRAEDER, Jens FRITSCHE, Daniel Johannes KOWALEWSKI, Michael ROEMER, Oliver SCHOOR
  • Amidated peptides and their deamidated counterparts displayed by HLA-A*02 for use in immunotherapy against different types of cancers
    Patent number: 11969464
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 23, 2023
    Date of Patent: April 30, 2024
    Inventors: Jens Hukelmann, Heiko Schuster, Ricarda Hannen, Christoph Schraeder, Jens Fritsche, Franziska Hoffgaard, Daniel Johannes Kowalewski, Oliver Schoor
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240132570
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 4, 2024
    Publication date: April 25, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Lena WULLKOPF, Christoph SCHRAEDER, Jens FRITSCHE, Daniel Johannes KOWALEWSKI, Michael ROEMER, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240131131
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 18, 2023
    Publication date: April 25, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240117003
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 5, 2023
    Publication date: April 11, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Lena WULLKOPF, Christoph SCHRAEDER, Jens FRITSCHE, Daniel Johannes KOWALEWSKI, Michael ROEMER, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240117004
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 18, 2023
    Publication date: April 11, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Lena WULLKOPF, Christoph SCHRAEDER, Jens FRITSCHE, Daniel Johannes KOWALEWSKI, Michael ROEMER, Oliver SCHOOR
  • Amidated peptides and their deamidated counterparts displayed by non-HLA-A*02 for use in immunotherapy against different types of cancers preliminary class
    Patent number: 11952409
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 24, 2023
    Date of Patent: April 9, 2024
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Hukelmann, Heiko Schuster, Lena Wullkopf, Christoph Schraeder, Jens Fritsche, Daniel Johannes Kowalewski, Michael Roemer, Oliver Schoor
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240109949
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 5, 2023
    Publication date: April 4, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Lena WULLKOPF, Christoph SCHRAEDER, Jens FRITSCHE, Daniel Johannes KOWALEWSKI, Michael ROEMER, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240075119
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 22, 2023
    Publication date: March 7, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240075118
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 18, 2023
    Publication date: March 7, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240067697
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO:1 to SEQ ID NO:113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 18, 2023
    Publication date: February 29, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Lena WULLKOPF, Christoph SCHRAEDER, Jens FRITSCHE, Daniel Johannes KOWALEWSKI, Michael ROEMER, Oliver SCHOOR
  • Amidated peptides and their deamidated counterparts displayed by HLA-A*02 for use in immunotherapy against different types of cancers
    Patent number: 11904003
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 17, 2023
    Date of Patent: February 20, 2024
    Assignee: Immatics Biotechnologies GMBH
    Inventors: Jens Hukelmann, Heiko Schuster, Ricarda Hannen, Christoph Schraeder, Jens Fritsche, Franziska Hoffgaard, Daniel Johannes Kowalewski, Oliver Schoor
  • Amidated peptides and their deamidated counterparts displayed by non-HLA-a*02 for use in immunotherapy against different types of cancers
    Patent number: 11891427
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 29, 2021
    Date of Patent: February 6, 2024
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Hukelmann, Heiko Schuster, Lena Wullkopf, Christoph Schraeder, Jens Fritsche, Daniel Johannes Kowalewski, Michael Roemer, Oliver Schoor
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240024440
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 11, 2023
    Publication date: January 25, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240024441
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 25, 2023
    Publication date: January 25, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240016907
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 10, 2023
    Publication date: January 18, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240016906
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 10, 2023
    Publication date: January 18, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240016911
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 25, 2023
    Publication date: January 18, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR